Misako Nagasaka, MD, PhD, describes how it is a “great time to be a thoracic oncologist” with the constantly expanding armamentarium in the field. She specifically discusses the available treatment options in frontline EGFR mutation–positive advanced non–small cell lung cancer and what particular clinical and lifestyle benefits are provided by the treatment regimen of subcutaneous amivantamab plus lazertinib.
Misako Nagasaka, MD, PhD, discusses practical considerations for oncologists implementing subcutaneous (SC) vs intravenous (IV) amivantamab plus lazertinib in the frontline setting for patients with EGFR-mutated advanced or metastatic non–small cell lung cancer. Nagasaka recommends the SC over the IV regimen in the frontline setting, particularly when focusing on convenience and patients’ quality of life.
Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. The prophylactic anticoagulation is particularly recommended for the first 4 months of treatment, when the risk of VTE is highest.
Misako Nagasaka, MD, PhD, discusses optimizing patient management when administering frontline SC amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. She describes how the majority of adverse events (AEs) with the SC regimen in the PALOMA-2 trial occurred during first 4 months of treatment. According to Nagasaka, this highlights the importance of early patient counseling regarding expectations and reporting of AEs when starting the SC regimen.
Misako Nagasaka, MD, PhD, describes the tolerability results with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced non–small cell lung cancer from the PALOMA-2 trial. She explains that the data thus far have shown comparable discontinuation rates related to adverse events for the SC regimen compared with what has been observed with intravenous amivantamab regimens in prior studies.
Misako Nagasaka, MD, PhD, discusses the overall response rate and duration of response with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced non–small cell lung cancer, as reported from the PALOMA-2 trial. She explains the significance of the durability demonstrated by the SC regimen in the frontline setting for EGFR-mutated advanced NSCLC.
Misako Nagasaka, MD, PhD, highlights progression-free survival data from the PALOMA-2 study among patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) receiving subcutaneous amivantamab plus lazertinib in the first-line setting. She compares these data with PFS data from the MARIPOSA trial, which evaluated intravenous amivantamab plus lazertinib in similar NSCLC populations.
Misako Nagasaka, MD, PhD, discusses results from the treatment-naïve populations in the PALOMA-2 study, which evaluated subcutaneous amivantamab plus lazertinib in patients with EGFR-mutated advanced or metastatic non–small cell lung cancer. She highlights study cohorts that explored the frontline combination using amivantamab every 2 weeks and every 4 weeks.
The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging EGFR therapies. Novel bispecific antibodies and ADCs may shift treatment. Key insights include resistance monitoring and proactive AE management.
The panelist discusses how, Healthcare professionals use osimertinib 1L for EGFR-mutated NSCLC, re-testing at progression for resistance mutations. MARIPOSA data refine 1L choices by predicting resistance pathways, guiding optimal sequencing.
The panelist discusses how, Healthcare professionals manage distinct toxicities with ami+laz (IRRs, rash) and osi+chemotherapyctx (cytopenias, diarrhea, fatigue). SKIPPirr informs IRR mitigation in ami’s first infusion. Proactive AE strategies include premedication, dose adjustments, supportive care, and monitoring.
The panelist discusses how, regarding the patient case, she will review the FDA approved options for the patient, including the combination of amivantamab + Lazertinib, osimertinib/chemotherapy, or single agent osimertinib.
The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular profile, comorbidities, and performance status. When discussing options with high-risk patients, healthcare professionals typically take a shared decision-making approach, thoroughly explaining both potential benefits and side effect management strategies. These conversations weigh factors like quality-of-life impact, monitoring requirements, and individual patient preferences to arrive at an optimal treatment strategy.
Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient presents to her primary care physician (PCP) with continued dry cough, dyspnea, and weight loss. She has a history of hypertension, previously managed on an ACE inhibitor, but is now on atenolol.
